248 related articles for article (PubMed ID: 26861738)
1. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy.
Wink KC; Belderbos JS; Dieleman EM; Rossi M; Rasch CR; Damhuis RA; Houben RM; Troost EG
Radiother Oncol; 2016 Mar; 118(3):453-9. PubMed ID: 26861738
[TBL] [Abstract][Full Text] [Related]
2. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
Sher DJ; Gielda BT; Liptay MJ; Warren WH; Batus M; Fidler MJ; Garg S; Bonomi P
Clin Lung Cancer; 2013 Jul; 14(4):370-5. PubMed ID: 23260389
[TBL] [Abstract][Full Text] [Related]
4. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
[TBL] [Abstract][Full Text] [Related]
6. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
Gielda BT; Mehta P; Khan A; Marsh JC; Zusag TW; Warren WH; Fidler MJ; Abrams RA; Bonomi P; Liptay M; Faber LP
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):985-91. PubMed ID: 20932684
[TBL] [Abstract][Full Text] [Related]
7. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer.
Katsui K; Ogata T; Watanabe K; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Acta Med Okayama; 2021 Jun; 75(3):269-277. PubMed ID: 34176930
[TBL] [Abstract][Full Text] [Related]
13. A pilot trial of consolidation bevacizumab after hypo-fractionated concurrent chemoradiotherapy in patients with unresectable locally advanced non-squamous non-small-cell lung cancer.
Huo L; Chu C; Jiang X; Zheng S; Zhang P; Zhou R; Chen N; Guo J; Qiu B; Liu H
Cancer Med; 2023 Sep; 12(17):17638-17647. PubMed ID: 37537968
[TBL] [Abstract][Full Text] [Related]
14. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
15. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
[TBL] [Abstract][Full Text] [Related]
16. Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Van De Voorde L; Janssen L; Larue R; Houben R; Buijsen J; Sosef M; Vanneste B; Schraepen MC; Berbée M; Lambin P
Eur J Surg Oncol; 2015 Oct; 41(10):1333-9. PubMed ID: 26091848
[TBL] [Abstract][Full Text] [Related]
17. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
18. Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.
Zhu ZF; Ma HL; Fan M; Bao Y; Zhuang TT; Chen M; Jiang GL; Fu XL
Technol Cancer Res Treat; 2014 Jun; 13(3):269-75. PubMed ID: 24066952
[TBL] [Abstract][Full Text] [Related]
19. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Wang Y; Li Y; Xia L; Niu K; Chen X; Lu D; Kong R; Chen Z; Sun J
Clin Transl Oncol; 2018 Mar; 20(3):366-373. PubMed ID: 28776311
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
